Genetics and Heart Health After Cancer Therapy

Inclusion Criteria * ≥18 years of age * Initial diagnosis of Breast Cancer in 2005 or later * Documented BRCA testing (results from a local laboratory are acceptable) showing * confirmation of a germline mutation in BRCA1 or BRCA2 that is predicted or suspected to be deleterious OR * confirmation that no mutation was detected in BRCA1 or BRCA2 * Non-carriers will have been treated with an anthracycline-based chemotherapy regimen; carriers may or may not have been treated with an anthracycline-based chemotherapy regimen. * Approximately at least 12 months from initiation of adjuvant treatment or neo-adjuvant chemotherapy * Able to provide informed consent Exclusion Criteria * Stage IV Breast Cancer * Genetic testing confirming a variant of unknown significance (VUS) or benign polymorphism in BRCA1 or BRCA2 * V02 Testing contraindicated for any reason, including: * Myocardial infarction (within past 3 months) * High-risk unstable angina; * High-risk or uncontrolled cardiac arrhythmias; * Symptomatic severe aortic stenosis; * Uncontrolled symptomatic heart failure; * Acute pulmonary embolus or pulmonary infarction; * Acute myocarditis or pericarditis; * Acute aortic dissection; * Coronary revascularization procedure within the past three months; * Uncontrolled hypertension, defined as systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg; * Clinically significant valvular heart disease (severe stenosis or regurgitation); * Known…